Iridex CorpIRIX

Iridescent losses: Iridex Corporation, the 35-year-old purveyor of retina and glaucoma lasers, just told the SEC that its last annual meeting produced vote totals “the product of a stealth proxy campaign” involving at least one unnamed actor, leaving the board to treat the result like a surprise party they didn’t invite themselves to. Rather than celebrate, directors are now suing for peace-or at least for a clearer guest list. (source: IRIX 8-K (2026-07-16), https://www.sec.gov/Archives/edgar/data/1006045/000119312526305344/d101758d8k.htm)

What Iridex actually makes are laser systems that ophthalmologists use to zap retinas and lower eye pressure, products it has been hawking since the Reagan administration. The company’s marketing copy still preens over “global leadership” and “35 years of innovation,” but the 10-Q ending 4 April 2026 tells the cash-coloured truth: $11.8 million of revenue, a half-million-dollar net loss, and a single customer-Topcon-taking 27% of sales. That’s concentration so tight it looks less like a customer base and more like a supply-chain hostage situation. (source: IRIX 10-Q (2026-05-19), https://www.sec.gov/Archives/edgar/data/1006045/000119312526230789/irix-20260404.htm)

The numbers read like a start-up’s dry-run disaster: $4.6 million of cash on the balance sheet, $23.5 million of liabilities, and operating cash outflows of $1.3 million for the quarter. Research and development chewed through $905,000, which is polite chump change compared with the $9.3 million of inventory sitting on the shelf-an increase of $1.4 million that could either be pre-sales stockpiling or the optical equivalent of yesterday’s newspapers. Diluted EPS came in at minus three cents on 17.3 million shares, a figure that invites you to wonder whether the board’s next product line will be share consolidation rather than shareholder value. (source: IRIX 10-Q (2026-05-19), https://www.sec.gov/Archives/edgar/data/1006045/000119312526230789/irix-20260404.htm)

The company’s press releases still glow with anniversary fanfare-European patents for MicroPulse, new retina lasers launched in 2023, and booth bookings at glaucoma congresses-but none of these milestones appear in the latest financials. Instead, the 10-Q quietly notes that Topcon’s exclusivity deal, inked back in 2021, remains in force, which explains why one customer can still command nearly a third of revenue. Iridex’s own investor-relations slide deck might call this “strategic focus,” but the filing calls it “more than 10% of total revenues” for two consecutive quarters. (source: IRIX 10-Q (2026-05-19), https://www.sec.gov/Archives/edgar/data/1006045/000119312526230789/irix-20260404.htm)

For investors hunting for a chart route, the SEC submissions JSON shows a CIK 1006045 ticker that trades on OTC Markets under the symbol IRIX, where thin liquidity and wide spreads mean any price you see is less a reflection of fundamentals and more a reflection of who happens to be logged into the OTC portal at 10:17 a.m. Pacific. The renderer’s chart rail will display the last print, but treat it like a weather vane in a hurricane: directional, not directionalisable. (source: IRIX SEC submissions JSON, https://data.sec.gov/submissions/CIK0001006045.json)

What changed in the past month is the board’s admission that it did not author the proxy campaign that elected the directors, a statement that sits somewhere between “security breach” and “corporate prank” and raises the question of whether the next board election will be held via carrier pigeon. What hasn’t changed is the balance sheet’s need for either a capital injection or a fire sale; the company’s $4.7 million of shareholders’ equity is the arithmetic equivalent of a polite invitation to start bargain-hunting for lasers. (source: IRIX SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001006045.json)

The product pipeline is real: European patents for MicroPulse, new retina lasers in the US, and booths at glaucoma congresses, but none of these announcements have yet shown up as revenue. Meanwhile, the 10-Q quietly discloses that Topcon’s exclusivity deal, signed in 2021, remains the main event, which explains why one customer can still take 27% of sales. The filing calls this “more than 10% of total revenues” for two consecutive quarters, which is corporate language for “don’t put all your lasers in one Topcon basket.” (source: IRIX 10-Q (2026-05-19), https://www.sec.gov/Archives/edgar/data/1006045/000119312526230789/irix-20260404.htm)